We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




Interaction of Transcription Factors Can Predict DNA Binding

By LabMedica International staff writers
Posted on 13 Feb 2019
A team of Swiss stem cell researchers has demonstrated that by observing the binding of transcription factors to mitotic chromosomes it is possible to predict how they will bind non-specifically to DNA.

A transcription factor (TF) (or sequence-specific DNA-binding factor) is a protein that controls the rate of transcription of genetic information from DNA to messenger RNA, by binding to a specific DNA sequence. More...
The function of TFs is to regulate genes in order to make sure that they are expressed in the right cell at the right time and in the right amount throughout the life of the cell and the organism.

TFs regulate gene expression by binding regulatory sequences of target genes. TF ability to occupy specific genomic sites depends on their nuclear concentration, their ability to search the genome, and the chromatin environment of their binding sites. How TFs maximize search efficiency for specific sites is not well understood. To clarify this matter, investigators at Ecole Polytechnique Fédérale de Lausanne (Switzerland) analyzed 501 TFs in mouse embryonic stem cells by determining how they bound to mitotic chromosomes, a property that has been linked to the ability of TFs to associate with DNA in a non-specific manner.

For this study, the investigators combined quantitative measurements of mitotic chromosome binding (MCB), TF mobility measurements by fluorescence recovery after photobleaching, single molecule imaging of DNA binding, and mapping of TF binding and chromatin accessibility.

Results published in the January 30, 2019, online edition of the journal Nature Communications revealed that TFs associating to mitotic chromosomes were enriched in DNA-rich compartments in interphase and displayed slower mobility in interphase and mitosis. MCB correlated with interphase TF properties such as sub-nuclear localization, mobility, and with large differences in TF ability to occupy specific genomic sites. Based on these findings, the investigators proposed that the co-localization of TFs with mitotic chromosomes was a proxy for TF non-specific DNA binding properties, which regulated TF search efficiency for their specific binding sites and thereby their impact on chromatin accessibility.

"Transcription factors differ largely in their ability to scan the genome to find their specific binding sites, and these differences can be predicted by simply looking at how much they bind to mitotic chromosomes," said senior author Dr. David M. Suter, assistant professor of stem cell research at Ecole Polytechnique Fédérale de Lausanne. "Transcription factors that are the most efficient in searching the genome could be able to drive broad changes in gene expression patterns even when expressed at low concentrations, and can therefore be particularly important for cell fate decision processes."

Related Links:
Ecole Polytechnique Fédérale de Lausanne


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Glucose Tolerance Test
NERL Trutol
New
Francisella Tularensis Test
TULAREMIA VIRCLIA IgG+IgM MONOTEST
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: Switching to an experimental drug after liquid biopsy detection of breast cancer recurrence can improve outcomes (Photo courtesy of Shutterstock)

Treatment Switching Guided by Liquid Biopsy Blood Tests Improves Outcomes for Breast Cancer Patients

Standard treatment for patients with advanced estrogen receptor (ER)-positive, HER2-negative breast cancer, a subtype driven by estrogen receptors that fuel tumor growth, often involves aromatase inhibitors,... Read more

Pathology

view channel
Image: Microscopy image of invasive breast cancer cells degrading their underlying extracellular matrix (Photo courtesy of University of Turku)

Visualization Tool Illuminates Breast Cancer Cell Migration to Suggest New Treatment Avenues

Patients with breast cancer who progress from ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC) face a significantly worse prognosis, as metastatic disease remains incurable.... Read more

Technology

view channel
Image: The machine learning-based method delivers near-perfect survival estimates for PAC patients (Photo courtesy of Shutterstock)

AI Method Predicts Overall Survival Rate of Prostate Cancer Patients

Prostate adenocarcinoma (PAC) accounts for 99% of prostate cancer diagnoses and is the second most common cancer in men globally after skin cancer. With more than 3.3 million men in the United States diagnosed... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.